Khatri I, Tomar R, Ganesan K, Prasad GS, Subramanian S (March 2017). "Complete genome sequence and comparative genomics of the probiotic yeast Saccharomyces boulardii". Scientific Reports. 7 (1). s. 371. Bibcode:2017NatSR...7..371K. doi:10.1038/s41598-017-00414-2. PMC5428479 $2. PMID28336969. [Note on source: The authors assign strain names based on the supplier of the probiotic. Of these suppliers, Biocodex and EDRL both claim to use the CNCM I-745 strain on their website.]
Rajkowska K, Kunicka-Styczyńska A (January 2009). "Phenotypic and genotypic characterization of probiotic yeasts". Biotechnology & Biotechnological Equipment. 23 (supplement 1). ss. 662-5. doi:10.1080/13102818.2009.10818511.
McFarland LV, Bernasconi P (1993). "Saccharomyces boulardii: a review of an innovative biotherapeutic agent". Microb Ecol Health Dis. 6 (4). ss. 157-71. doi:10.3109/08910609309141323.
Liu JJ, Kong II, Zhang GC, Jayakody LN, Kim H, Xia PF, ve diğerleri. (April 2016). "Metabolic Engineering of Probiotic Saccharomyces boulardii". Applied and Environmental Microbiology. 82 (8). ss. 2280-2287. Bibcode:2016ApEnM..82.2280L. doi:10.1128/AEM.00057-16. PMC4959471 $2. PMID26850302.
"Scientific Opinion on the substantiation of health claims related to Saccharomyces cerevisiae var. boulardii CNCM I-1079 and defence against pathogenic gastro-intestinal microorganisms (ID 913, further assessment) pursuant to Article 13(1) of Regulation (EC) No 1924/2006". EFSA Journal (İngilizce). 10 (6). June 2012. doi:10.2903/j.efsa.2012.2717.
Kotowska M, Albrecht P, Szajewska H (March 2005). "Saccharomyces boulardii in the prevention of antibiotic-associated diarrhoea in children: a randomized double-blind placebo-controlled trial". Alimentary Pharmacology & Therapeutics. 21 (5). ss. 583-590. doi:10.1111/j.1365-2036.2005.02356.x. PMID15740542.
Doron SI, Hibberd PL, Gorbach SL (July 2008). "Probiotics for prevention of antibiotic-associated diarrhea". Journal of Clinical Gastroenterology. 42 (Suppl 2). ss. S58-S63. doi:10.1097/MCG.0b013e3181618ab7. PMID18542041.
Surawicz CM (July 2008). "Role of probiotics in antibiotic-associated diarrhea, Clostridium difficile-associated diarrhea, and recurrent Clostridium difficile-associated diarrhea". Journal of Clinical Gastroenterology. 42 (Suppl 2). ss. S64-S70. doi:10.1097/MCG.0b013e3181646d09. PMID18545161.
Szajewska H, Kołodziej M (October 2015). "Systematic review with meta-analysis: Saccharomyces boulardii in the prevention of antibiotic-associated diarrhoea". Alimentary Pharmacology & Therapeutics. 42 (7). ss. 793-801. doi:10.1111/apt.13344. PMID26216624.
Guo Q, Goldenberg JZ, Humphrey C, El Dib R, Johnston BC (April 2019). "Probiotics for the prevention of pediatric antibiotic-associated diarrhea". The Cochrane Database of Systematic Reviews. 4 (4). ss. CD004827. doi:10.1002/14651858.CD004827.pub5. PMC6490796 $2. PMID31039287.
Tung JM, Dolovich LR, Lee CH (December 2009). "Prevention of Clostridium difficile infection with Saccharomyces boulardii: a systematic review". Canadian Journal of Gastroenterology. 23 (12). ss. 817-821. doi:10.1155/2009/915847. PMC2805518 $2. PMID20011734.
Szajewska H, Horvath A, Kołodziej M (June 2015). "Systematic review with meta-analysis: Saccharomyces boulardii supplementation and eradication of Helicobacter pylori infection". Alimentary Pharmacology & Therapeutics. 41 (12). ss. 1237-1245. doi:10.1111/apt.13214. PMID25898944.
Roberts T, Stark D, Harkness J, Ellis J (28 Mayıs 2014). "Update on the pathogenic potential and treatment options for Blastocystis sp". Gut Pathogens. Cilt 6. s. 17. doi:10.1186/1757-4749-6-17. PMC4039988 $2. PMID24883113.
Dinleyici EC, Eren M, Dogan N, Reyhanioglu S, Yargic ZA, Vandenplas Y (March 2011). "Clinical efficacy of Saccharomyces boulardii or metronidazole in symptomatic children with Blastocystis hominis infection". Parasitology Research. 108 (3). ss. 541-545. doi:10.1007/s00436-010-2095-4. PMID20922415.
Szajewska H, Guarino A, Hojsak I, Indrio F, Kolacek S, Shamir R, ve diğerleri. (April 2014). "Use of probiotics for management of acute gastroenteritis: a position paper by the ESPGHAN Working Group for Probiotics and Prebiotics". Journal of Pediatric Gastroenterology and Nutrition. 58 (4). ss. 531-539. doi:10.1097/MPG.0000000000000320. PMID24614141.
Capece A, Romaniello R, Pietrafesa A, Siesto G, Pietrafesa R, Zambuto M, Romano P (November 2018). "Use of Saccharomyces cerevisiae var. boulardii in co-fermentations with S. cerevisiae for the production of craft beers with potential healthy value-added". International Journal of Food Microbiology. Cilt 284. ss. 22-30. doi:10.1016/j.ijfoodmicro.2018.06.028. PMID29990636.
Stenman LK, Burcelin R, Lahtinen S (February 2016). "Establishing a causal link between gut microbes, body weight gain and glucose metabolism in humans - towards treatment with probiotics". Beneficial Microbes. 7 (1). ss. 11-22. doi:10.3920/BM2015.0069. PMID26565087.
Santino I, Alari A, Bono S, Teti E, Marangi M, Bernardini A, ve diğerleri. (2014). "Saccharomyces cerevisiae fungemia, a possible consequence of the treatment of Clostridium difficile colitis with a probioticum". International Journal of Immunopathology and Pharmacology. 27 (1). ss. 143-146. doi:10.1177/039463201402700120. PMID24674691.
Kelesidis T, Pothoulakis C (March 2012). "Efficacy and safety of the probiotic Saccharomyces boulardii for the prevention and therapy of gastrointestinal disorders". Therapeutic Advances in Gastroenterology. 5 (2). ss. 111-125. doi:10.1177/1756283X11428502. PMC3296087 $2. PMID22423260.
Sulik-Tyszka B, Snarski E, Niedźwiedzka M, Augustyniak M, Myhre TN, Kacprzyk A, ve diğerleri. (June 2018). "Experience with Saccharomyces boulardii Probiotic in Oncohaematological Patients". Probiotics and Antimicrobial Proteins. 10 (2). ss. 350-355. doi:10.1007/s12602-017-9332-4. PMC5973998 $2. PMID28948565.
europa.eu
ema.europa.eu
"Active substance: Saccharomyces boulardii"(PDF). List of nationally authorised medicinal products. European Medicines Agency. 15 Ekim 2020. 30 Haziran 2024 tarihinde kaynağından arşivlendi(PDF). Erişim tarihi: 4 Aralık 2020.
Toma MM, Raipulis J, Kalnina I, Rutkis R (June 2005). "Effect of Probiotic Yeast on Genotoxicity"(PDF). Food Technology and Biotechnology. Cilt 43. ss. 301-05. 2 Aralık 2020 tarihinde kaynağından arşivlendi(PDF). Erişim tarihi: 18 Ocak 2014.
Soccol CR, Vandenberghe LP, Spier MR, Medeiros AB, Yamaguishi CT, Lindner JD, Pandey A, Thomaz-Soccol V (June 2010). "The Potential of Probiotics: A Review"(PDF). Food Technology and Biotechnology. Cilt 48. ss. 413-34. 2 Aralık 2020 tarihinde kaynağından arşivlendi(PDF). Erişim tarihi: 18 Ocak 2014.
harvard.edu
adsabs.harvard.edu
Khatri I, Tomar R, Ganesan K, Prasad GS, Subramanian S (March 2017). "Complete genome sequence and comparative genomics of the probiotic yeast Saccharomyces boulardii". Scientific Reports. 7 (1). s. 371. Bibcode:2017NatSR...7..371K. doi:10.1038/s41598-017-00414-2. PMC5428479 $2. PMID28336969. [Note on source: The authors assign strain names based on the supplier of the probiotic. Of these suppliers, Biocodex and EDRL both claim to use the CNCM I-745 strain on their website.]
Liu JJ, Kong II, Zhang GC, Jayakody LN, Kim H, Xia PF, ve diğerleri. (April 2016). "Metabolic Engineering of Probiotic Saccharomyces boulardii". Applied and Environmental Microbiology. 82 (8). ss. 2280-2287. Bibcode:2016ApEnM..82.2280L. doi:10.1128/AEM.00057-16. PMC4959471 $2. PMID26850302.
Khatri I, Tomar R, Ganesan K, Prasad GS, Subramanian S (March 2017). "Complete genome sequence and comparative genomics of the probiotic yeast Saccharomyces boulardii". Scientific Reports. 7 (1). s. 371. Bibcode:2017NatSR...7..371K. doi:10.1038/s41598-017-00414-2. PMC5428479 $2. PMID28336969. [Note on source: The authors assign strain names based on the supplier of the probiotic. Of these suppliers, Biocodex and EDRL both claim to use the CNCM I-745 strain on their website.]
Liu JJ, Kong II, Zhang GC, Jayakody LN, Kim H, Xia PF, ve diğerleri. (April 2016). "Metabolic Engineering of Probiotic Saccharomyces boulardii". Applied and Environmental Microbiology. 82 (8). ss. 2280-2287. Bibcode:2016ApEnM..82.2280L. doi:10.1128/AEM.00057-16. PMC4959471 $2. PMID26850302.
McFarland LV, Surawicz CM, Greenberg RN, Elmer GW, Moyer KA, Melcher SA, ve diğerleri. (March 1995). "Prevention of beta-lactam-associated diarrhea by Saccharomyces boulardii compared with placebo". The American Journal of Gastroenterology. 90 (3). ss. 439-448. PMID7872284.
Kotowska M, Albrecht P, Szajewska H (March 2005). "Saccharomyces boulardii in the prevention of antibiotic-associated diarrhoea in children: a randomized double-blind placebo-controlled trial". Alimentary Pharmacology & Therapeutics. 21 (5). ss. 583-590. doi:10.1111/j.1365-2036.2005.02356.x. PMID15740542.
Doron SI, Hibberd PL, Gorbach SL (July 2008). "Probiotics for prevention of antibiotic-associated diarrhea". Journal of Clinical Gastroenterology. 42 (Suppl 2). ss. S58-S63. doi:10.1097/MCG.0b013e3181618ab7. PMID18542041.
Surawicz CM (July 2008). "Role of probiotics in antibiotic-associated diarrhea, Clostridium difficile-associated diarrhea, and recurrent Clostridium difficile-associated diarrhea". Journal of Clinical Gastroenterology. 42 (Suppl 2). ss. S64-S70. doi:10.1097/MCG.0b013e3181646d09. PMID18545161.
Szajewska H, Kołodziej M (October 2015). "Systematic review with meta-analysis: Saccharomyces boulardii in the prevention of antibiotic-associated diarrhoea". Alimentary Pharmacology & Therapeutics. 42 (7). ss. 793-801. doi:10.1111/apt.13344. PMID26216624.
Guo Q, Goldenberg JZ, Humphrey C, El Dib R, Johnston BC (April 2019). "Probiotics for the prevention of pediatric antibiotic-associated diarrhea". The Cochrane Database of Systematic Reviews. 4 (4). ss. CD004827. doi:10.1002/14651858.CD004827.pub5. PMC6490796 $2. PMID31039287.
Tung JM, Dolovich LR, Lee CH (December 2009). "Prevention of Clostridium difficile infection with Saccharomyces boulardii: a systematic review". Canadian Journal of Gastroenterology. 23 (12). ss. 817-821. doi:10.1155/2009/915847. PMC2805518 $2. PMID20011734.
Szajewska H, Horvath A, Kołodziej M (June 2015). "Systematic review with meta-analysis: Saccharomyces boulardii supplementation and eradication of Helicobacter pylori infection". Alimentary Pharmacology & Therapeutics. 41 (12). ss. 1237-1245. doi:10.1111/apt.13214. PMID25898944.
Roberts T, Stark D, Harkness J, Ellis J (28 Mayıs 2014). "Update on the pathogenic potential and treatment options for Blastocystis sp". Gut Pathogens. Cilt 6. s. 17. doi:10.1186/1757-4749-6-17. PMC4039988 $2. PMID24883113.
Dinleyici EC, Eren M, Dogan N, Reyhanioglu S, Yargic ZA, Vandenplas Y (March 2011). "Clinical efficacy of Saccharomyces boulardii or metronidazole in symptomatic children with Blastocystis hominis infection". Parasitology Research. 108 (3). ss. 541-545. doi:10.1007/s00436-010-2095-4. PMID20922415.
Szajewska H, Guarino A, Hojsak I, Indrio F, Kolacek S, Shamir R, ve diğerleri. (April 2014). "Use of probiotics for management of acute gastroenteritis: a position paper by the ESPGHAN Working Group for Probiotics and Prebiotics". Journal of Pediatric Gastroenterology and Nutrition. 58 (4). ss. 531-539. doi:10.1097/MPG.0000000000000320. PMID24614141.
Capece A, Romaniello R, Pietrafesa A, Siesto G, Pietrafesa R, Zambuto M, Romano P (November 2018). "Use of Saccharomyces cerevisiae var. boulardii in co-fermentations with S. cerevisiae for the production of craft beers with potential healthy value-added". International Journal of Food Microbiology. Cilt 284. ss. 22-30. doi:10.1016/j.ijfoodmicro.2018.06.028. PMID29990636.
Stenman LK, Burcelin R, Lahtinen S (February 2016). "Establishing a causal link between gut microbes, body weight gain and glucose metabolism in humans - towards treatment with probiotics". Beneficial Microbes. 7 (1). ss. 11-22. doi:10.3920/BM2015.0069. PMID26565087.
Santino I, Alari A, Bono S, Teti E, Marangi M, Bernardini A, ve diğerleri. (2014). "Saccharomyces cerevisiae fungemia, a possible consequence of the treatment of Clostridium difficile colitis with a probioticum". International Journal of Immunopathology and Pharmacology. 27 (1). ss. 143-146. doi:10.1177/039463201402700120. PMID24674691.
Kelesidis T, Pothoulakis C (March 2012). "Efficacy and safety of the probiotic Saccharomyces boulardii for the prevention and therapy of gastrointestinal disorders". Therapeutic Advances in Gastroenterology. 5 (2). ss. 111-125. doi:10.1177/1756283X11428502. PMC3296087 $2. PMID22423260.
Berni Canani R, Cucchiara S, Cuomo R, Pace F, Papale F (July 2011). "Saccharomyces boulardii: a summary of the evidence for gastroenterology clinical practice in adults and children". European Review for Medical and Pharmacological Sciences. 15 (7). ss. 809-822. PMID21780551.
Sulik-Tyszka B, Snarski E, Niedźwiedzka M, Augustyniak M, Myhre TN, Kacprzyk A, ve diğerleri. (June 2018). "Experience with Saccharomyces boulardii Probiotic in Oncohaematological Patients". Probiotics and Antimicrobial Proteins. 10 (2). ss. 350-355. doi:10.1007/s12602-017-9332-4. PMC5973998 $2. PMID28948565.
Toma MM, Raipulis J, Kalnina I, Rutkis R (June 2005). "Effect of Probiotic Yeast on Genotoxicity"(PDF). Food Technology and Biotechnology. Cilt 43. ss. 301-05. 2 Aralık 2020 tarihinde kaynağından arşivlendi(PDF). Erişim tarihi: 18 Ocak 2014.
Soccol CR, Vandenberghe LP, Spier MR, Medeiros AB, Yamaguishi CT, Lindner JD, Pandey A, Thomaz-Soccol V (June 2010). "The Potential of Probiotics: A Review"(PDF). Food Technology and Biotechnology. Cilt 48. ss. 413-34. 2 Aralık 2020 tarihinde kaynağından arşivlendi(PDF). Erişim tarihi: 18 Ocak 2014.
"Active substance: Saccharomyces boulardii"(PDF). List of nationally authorised medicinal products. European Medicines Agency. 15 Ekim 2020. 30 Haziran 2024 tarihinde kaynağından arşivlendi(PDF). Erişim tarihi: 4 Aralık 2020.